KURA Stock Risk & Deep Value Analysis
Kura Oncology Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About KURA Stock
We analyzed Kura Oncology Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KURA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is KURA Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for KURA?
- ⚠
Unexpected Regulatory Delays or Complete Response Letter (CRL)
- ⚠
Slower-than-anticipated Commercial Ramp-up post-launch
- ⚠
Emergence of a Superior Competitive Therapy in the NPM1-mutant AML space
- ⚠
Negative Safety Signals or Tolerability Issues in Broader Patient Population (post-approval)
Unlock KURA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Kura Oncology Inc (KURA) Do?
Market Cap
$1.04B
Sector
Healthcare
Industry
Biotechnology
Employees
192
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Visit Kura Oncology Inc WebsiteIs KURA Stock Undervalued?
Unlock the full AI analysis for KURA
Get the complete DVR score, risk analysis, and more
Does KURA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat for Kura Oncology is based on the intellectual property surrounding ziftomenib, its strong clinical profile, and the potential for regulatory exclusivity in a specific and underserved oncology indication. Successfully establishing ziftomenib as the standard of care post-approval would create significant switching costs for physicians and patients, reinforcing its position.
Moat Erosion Risks
- •Patent expiry or successful patent challenges from competitors
- •Emergence of highly effective competitive therapies or alternative treatment paradigms
- •Failure of confirmatory trials to validate accelerated approval
KURA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive KURA Stock Higher?
Near-Term (0-6 months)
- •Potential Accelerated Regulatory Approval Decision (PDUFA date or similar action) for ziftomenib in NPM1-mutant AML (Q2/Q3 2026)
- •Q1 2026 Earnings Report (Estimated early-May 2026) – focus on cash runway and regulatory updates
Medium-Term (6-18 months)
- •Commercial Launch of ziftomenib (Post-approval, late 2026/early 2027)
- •Initial Sales Performance Data and Physician Uptake Trends (H1 2027)
- •Updates on Confirmatory Trials or Potential Label Expansion Studies
Long-Term (18+ months)
- •Establishment of Ziftomenib as Standard of Care for NPM1-mutant AML (2028-2029)
- •Pipeline Progression/New Indications for Ziftomenib or other assets
- •Strategic Partnerships or Acquisition Interest from larger pharmaceutical companies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for KURA?
- ✓
Positive updates or accelerated approval decision for ziftomenib
- ✓
Initial commercial sales figures and physician adoption rates post-launch
- ✓
Continued healthy cash runway and effective capital allocation for commercialization and pipeline development
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for KURA (Kura Oncology Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
